Uveal Tract Anatomy & Physiology

The uvea is the eye's middle, pigmented, highly vascular layer between the outer fibrous coat (sclera/cornea) and the inner neurosensory retina, composed of the iris, ciliary body, and choroid; inflammation of any part is called uveitis.¹ The iris is the most anterior uveal structure, a pigmented diaphragm controlling pupil size via sphincter and dilator muscles. The ciliary body, just posterior to the iris root, has two functional parts: the pars plicata (produces aqueous humor, anchors lens zonules) and the pars plana (smooth posterior extension serving as the vitreous humor's attachment point). The choroid is the most posterior and extensive uveal structure, densely vascular, supplying the outer retina including photoreceptors and RPE. This subdivision directly defines uveitis classification: anterior uveitis affects the iris/ciliary body (41-60% of cases), intermediate uveitis affects the pars plana/peripheral retina (9-15%), posterior uveitis involves the choroid/retina (17-23%), and panuveitis involves all uveal layers (7-32%).¹

The eye, including the uveal tract, maintains immune privilege — tightly regulated tolerance limiting vision-threatening inflammation from minor antigenic challenge. This privilege is maintained through anatomical barriers (blood-ocular barriers), local immunomodulatory mediators, regulatory immune-cell interactions, and anterior chamber-associated immune deviation (ACAID), a form of systemic tolerance induced by intraocular antigen exposure.² Ocular immune privilege is best understood as dynamic and conditional rather than absolute: across autoimmune uveitis, corneal transplantation, AMD, diabetic retinopathy, ocular tumors, and allergic conjunctivitis, disease is generally associated with partial disruption, remodeling, or exploitation of these mechanisms rather than complete loss.² These alterations vary by ocular compartment but recurrently involve disrupted immune homeostasis, increased inflammatory signaling, altered leukocyte activity, impaired barrier integrity, and reduced local immune restraint.²

Untreated uveitis, regardless of anatomic subtype, can cause cataract, glaucoma, macular edema, retinal detachment, and optic nerve damage, reflecting the uvea's direct anatomic and vascular connections to the lens, angle, retina, and optic nerve.¹ Uveitis predominantly affects adults 20-50 years old; while a substantial proportion is idiopathic (27-51% in the US/Europe), 37-49% is associated with an identifiable systemic disease such as axial spondyloarthritis, underscoring why uveitis often warrants a systemic, not just ocular, workup.¹ Recognizing which elements of immune privilege are preserved or disrupted in a given setting helps explain why inflammation, transplantation, tumors, and allergy behave differently across ocular tissues, and may support more precise immune-directed treatment.²

• Uveitis anatomic classification (anterior, intermediate, posterior, panuveitis) directly maps onto which uveal structure is inflamed¹
• The pars plana, not the pars plicata, is the anatomic landmark defining intermediate uveitis and the site of vitreous base attachment¹
• Ocular immune privilege is a dynamic, conditional system, not an all-or-nothing state, maintained by anatomical barriers, local mediators, and ACAID-mediated tolerance²
• A substantial proportion of uveitis is linked to systemic disease, making a directed systemic review essential¹
• Common pitfall: treating "uveitis" as a single disease rather than a group of conditions defined by which anatomic compartment is involved¹
• Common pitfall: confusing the pars plicata (aqueous production, zonules) with the pars plana (vitreous attachment, intermediate uveitis landmark)
• Common pitfall: assuming ocular immune privilege is either fully intact or completely absent rather than a graded, context-dependent state²